Inclusion Criteria:
* Provide signed written ICF and voluntary consent prior to any mandatory study-specific procedures, sampling, and analyses.
* Histologically confirmed progressive, advanced (T4b, N+ or M1) urothelial carcinoma (UC)
* Measurable disease by RECIST 1.1
* DDR deficiency by local test
* PTGR1 overexpression as defined by local test
* ECOG performance status 0-1
* Minimum age of 18 years
* Life expectancy \> 3 months
* No prior treatment with acylfulvenes
* At least one prior line of systemic treatment. Patients ineligible for standard second-line treatment may be considered for inclusion.
* At least 4 weeks after major surgery or radiotherapy. Short-duration, limited-field radiotherapy for symptom control is allowed until 2 weeks before C1D1.
* Adequate organ function at screening defined as:
* Liver Function:
AST\*, ALT\* ≤3 × ULN or \<5 × ULN in cases of documented liver metastases or involvement of the liver in the disease process.
Total serum bilirubin\* ≤1.5 × ULN or \<5 × ULN if secondary to Gilbert's Syndrome or documented liver metastases or involvement of the liver in the disease process.
•Renal Function: Serum creatinine clearance ≥45 mL/min either measured or calcu-lated using the standard Cockcroft-Gault formula.
•Bone Marrow Function:ANC\* ≥1,5 × 10⁹/L. Hemoglobin\* ≥5,0 mmol/L (The use of transfusion or other interven-tion to achieve hemoglobin ≥5,0 mmol/L is acceptable. For those pa-tients undergoing RBC transfusion, hemoglobin must be evaluated at least 14 days after the last RBC transfusion).
Platelet count\* ≥100 × 10⁹/L (assessed ≥7 days following last platelet transfusion in patients with thrombocytopenia requiring platelets).
•Blood clotting function: INR\* and aPTT\* ≤1.5 × ULN. Patients on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for the intended use.
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 3 days of the first dose of LP-184. A woman is of child bearing potential unless she:
* has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy.
* is aged ≥60 years and is amenorrhoeic.
* is aged \<60 years and has been amenorrhoeic for ≥12 months (including no irregular menses or spotting) in the absence of any medication which induces a meno-pausal state and has documented ovarian failure by serum estradiol and follicle-stimulating hormone.
Women of childbearing potential must use highly effective contraception. Men of reproductive potential must agree to use highly effective contraceptive methods and avoid sperm donation during the study treatment and for 3 months after the last dose of LP-184. A man is of reproductive potential unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.
Regarding brain metastases, based on one of the following:
* No clinical evidence of brain metastases.
* Previously treated brain metastases that are either stable for at least 4 weeks since last treatment or progressed since prior local CNS therapy and not requiring imme-diate re-treatment with local therapy.
* Patients on a chronic stable dose of ≤2 mg total daily of dexamethasone (or equivalent) are eligible.
Exclusion Criteria:
* Exposure to anti-cancer therapy within 2 weeks or within at least 5 half-lives of the anti-cancer agent whichever is shorter; or 4 weeks from any biologics/immunotherapies or any investigational therapy prior to the first dose of LP-184. (Note: low-dose steroids (oral prednisone or equivalent ≤20 mg/day), localized non-CNS radiotherapy, previous hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate cancer, and treatment with bisphosphonates and RANKL inhibitors are not criteria for exclusion if such therapy has not been changed within 4 weeks before LP-184 treatment.)
* Any history of retinopathy and/or macular degeneration (without specifications or grades).
* Infection requiring antibiotics, antivirals, or antifungals within 1 week prior to first dose of study drug. Prophylactic therapy for e.g. urinary tract infections allowed.
* Hepatitis B and/or hepatitis C infection (determined on baseline hepatitis B and C screen) or known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV).
* Have clinically significant cardiac disease including:
* New York Heart Association Class IV heart failure.
* Myocardial infarction or stroke ≤3 months prior to the first dose of LP-184.
* Unstable angina within ≤12 weeks prior to the first dose of LP-184 unless the underlying disease has been corrected by procedural intervention e.g., stent, bypass.
* Severe aortic stenosis.
* Uncontrolled arrhythmia.
* QTc \>470 milliseconds by Fridericia criteria.
* Congenital long QT syndrome, or a QTcF interval \>470 ms (average of triplicate ECGs) at screening and on Cycle 1 Day 1 (pre-dose) except for a documented bundle branch block or unless secondary to a pacemaker.
* Have clinically significant AEs that have not resolved to baseline or ≤Grade 1 based on NCI-CTCAE prior to first dose of study drug, unless approved by the sponsor. Patients with chronic Grade 2 toxicities may be eligible at the discretion of the investigator, e.g. Grade 2 chemotherapy-induced neuropathy, alopecia, or hypothy-roidism from prior immunotherapy treatment).
* Have any other serious medical condition which, in the opinion of the investigator, would preclude the patient from study participation.
* Pregnant or breastfeeding women, or women of childbearing potential unwilling or unable to comply with contraception requirements.